company background image
ICLR logo

ICON NasdaqGS:ICLR 주식 보고서

최종 가격

US$212.76

시가총액

US$16.8b

7D

6.4%

1Y

-21.8%

업데이트

21 Nov, 2024

데이터

회사 재무 +

ICON Public Limited Company

NasdaqGS:ICLR 주식 보고서

시가총액: US$16.8b

ICLR 주식 개요

임상 연구 기관인 아이콘 퍼블릭 리미티드 컴퍼니는 아일랜드, 유럽 전역, 미국 및 전 세계에서 아웃소싱 개발 및 상용화 서비스를 제공하고 있습니다. 자세한 내용

ICLR 기본 분석
눈송이 점수
가치 평가6/6
미래 성장1/6
과거 실적5/6
재무 상태4/6
배당금0/6

보상

공정 가치 추정치보다 낮은 47% 에서 거래

수익은 매년 13.57% 증가할 것으로 예상됩니다.

지난 1년간 수익이 45.7% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

분석가들은 주가가 31.9% 상승할 것이라는 데 동의합니다.

위험 분석

위험 검사에서 ICLR 에 대한 위험이 감지되지 않았습니다.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Tactical Partnerships And Biotech Positivity To Boost Future Revenue Growth

Key Takeaways Strategic partnerships and award opportunities in new therapeutic areas are expected to drive revenue growth and increase market share. Cost management, improved processes, and technology leverage could enhance operational efficiency and positively impact earnings and shareholder value.
View narrative
US$282.06
FV
24.6% undervalued intrinsic discount
4.88%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
2 days ago author updated this narrative

ICON Public Limited Company 경쟁사

Avantor

NYSE:AVTR

US$13.7b

Bio-Techne

NasdaqGS:TECH

US$10.9b

Waters

NYSE:WAT

US$21.2b

Medpace Holdings

NasdaqGS:MEDP

US$10.1b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ICON
과거 주가
현재 주가US$212.76
52주 최고치US$347.72
52주 최저치US$183.38
베타1.25
11개월 변경-24.95%
3개월 변경 사항-34.37%
1년 변경 사항-21.76%
33년 변화-22.31%
5년 변화30.09%
IPO 이후 변화3,245.55%

최근 뉴스 및 업데이트

With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For

Nov 02
With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For

Recent updates

With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For

Nov 02
With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For

Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors

Sep 25
Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Sep 09
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt

Aug 25
We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt

An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued

Aug 10
An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued

ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)

Jul 13

Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)

Jun 14
Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)

Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching

May 30
Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching

ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

May 14
ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 28
ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

Apr 21
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

Apr 05
ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

Mar 05
ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Feb 07
With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?

Feb 01

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Jan 23
These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

Jan 08
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E

Dec 24
What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E

A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Dec 09
A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Nov 08
With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Oct 09
Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Sep 23
Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Sep 05
Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?

Aug 03
Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

Jun 30
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Jun 12
Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

May 23
Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Mar 29
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Mar 11
Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?

Feb 21
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Dec 28
Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Dec 10
These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?

Nov 22
Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?

Icon selected by BARDA to conduct anthrax vaccine clinical trial

Oct 06

Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?

Sep 15
Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?

ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly

Aug 26
ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly

Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth

Aug 11

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?

Aug 01
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?

주주 수익률

ICLRUS Life SciencesUS 마켓
7D6.4%-2.3%0.3%
1Y-21.8%3.1%31.1%

수익률 대 산업: ICLR 지난 1년 동안 3.1 %를 반환한 US Life Sciences 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ICLR 지난 1년 동안 31.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ICLR's price volatile compared to industry and market?
ICLR volatility
ICLR Average Weekly Movement7.6%
Life Sciences Industry Average Movement8.8%
Market Average Movement6.2%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

안정적인 주가: ICLR 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ICLR 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립직원CEO웹사이트
199042,250Steve Cutlerwww.iconplc.com

임상 연구 기관인 아이콘 퍼블릭 리미티드 컴퍼니는 아일랜드, 유럽 전역, 미국 및 국제적으로 아웃소싱 개발 및 상용화 서비스를 제공합니다. 이 회사는 화합물 선택부터 1-4상 임상시험까지 임상 개발 프로세스의 다양한 단계를 지원하는 프로그램의 전략적 개발, 관리 및 분석을 전문으로 합니다. 또한 개발의 모든 단계, 승인 전후, 데이터 솔루션, 시험기관 및 환자 접근 서비스를 포함한 임상 개발 서비스, 임상시험 관리, 컨설팅 및 계약 인력 서비스, 임상 개발 전략, 계획 및 시험 설계, 전체 연구 실행, 시판 후 상업화로 구성된 상업 서비스도 제공합니다.

ICON Public Limited Company 기본 사항 요약

ICON 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ICLR 기본 통계
시가총액US$16.81b
수익(TTM)US$747.89m
수익(TTM)US$8.31b

23.5x

P/E 비율

2.1x

P/S 비율

ICLR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ICLR 손익 계산서(TTM)
수익US$8.31b
수익 비용US$5.85b
총 이익US$2.46b
기타 비용US$1.71b
수익US$747.89m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)9.06
총 마진29.64%
순이익 마진9.00%
부채/자본 비율35.1%

ICLR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기